Original research articleFirst-time use of newer oral contraceptives and the risk of venous thromboembolism☆
References (22)
- et al.
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
Lancet
(1995) - et al.
Population-based study of risk of venous thromboembolism associated with various oral contraceptives
Lancet
(1997) - et al.
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components [see also comments]
Lancet
(1995) - et al.
End of the line for “third-generation-pill” controversy?
Lancet
(1997) - et al.
Oral contraceptives and thrombotic diseases: impact of new epidemiological studies
Contraception
(1996) - et al.
The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research
Contraception
(1996) Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time
J Clin Epidemiol
(1989)- et al.
Principles of non-experimental assessment of excess risk, with special reference to adverse drug reactions
J Clin Epidemiol
(1989) The evolution of clinical practice and time trends in drug effects
J Clin Epidemiol
(1994)- et al.
Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study
Cited by (0)
- ☆
Funded in part by grants from Organon, Schering AG, and the Fonds de la Recherche en Santé du Québec (FRSQ). Samy Suissa is a Senior Research Scholar of the FRSQ. Lucie Blais is the recipient of a doctoral scholarship from the National Health and Development Program of Canada (NHRDP). The McGill Pharmacoepidemiology Research Unit is funded by the FRSQ.
Copyright © 1997 Published by Elsevier Inc.